Gapping up
In reaction to strong earnings/guidance:
- ESIO +30.3%, NBIX +19.2%, TACT +12.2%, WSTL +11.3%, FMSA +11.2%, PEI +9.7%, SBRA +9.2%, CBPO +8.4%, IMDZ +7.7%, LB +7.5%, (October comps of +2% vs lsd decline prior guidance; sees Q3 EPS to be at the high end of its guidance and reiterates FY 17 EPS guidance of $3.00-3.20; expects Q3 sales of $2618 mln vs $2568 mln consensus), KMT +7.3%, QDEL +6.3%, EXEL +6.1%, ANSS +5.5%, WTI +5.4%, CZR +5%, APRN +4.7%, AN +4.6%, CFMS +4.5%, ABC +4.4%, BLDP +4.1%, HOS +4.1%, CKH +3.7%, RWLK +3.6%, MYRG +3.5%, ZAGG +3.5%, ZAGG +3.5%, SHAK +3.5%, ULTI +3.4%, CMPR +3.3%, HBM +3.2%, GLUU +3.1%, JUNO +3.1%, HIIQ +3.1%, AREX +2.9%, INAP +2.9%, NMIH +2.8%, TNH +2.7%, DLPH +2.7%, BABA +2.6%, CVE +2.6%, DXCM +2.5%, CF +2.5%, SWM +2.4%, SRC +2%, ALL +1.9%, RGLD +1.7%, ARRS +1.6%, AME +1.6%, SRCI +1.5%, ZUMZ +1.4%, (October comps of +6.6% vs +10.2% year ago and +9.3% last month), ADP +1.3%, BOJA +1.2%, EQIX +1.1%, FLT +1.1%, CI +1.1%, DWDP +1.1%, QCOM +0.9%
M&A news:
- OCRX +65% (to be acquired by Mallinckrodt (MNK) for an upfront payment of $1.52/share and a CVR for up to $2.58/share)
Other news:
- XTNT +14.7% (enters into a distribution agreement with curasan, ' adding a premium line of synthetic scaffolds to its biologics portfolio' )
- DRNA +10.8% (Dicerna Pharmaceuticals and Boehringer Ingelheim announce a research collaboration and license agreement to discover and develop novel GalXC RNAi therapeutics for the treatment of chronic liver diseases)
- TURN +8% (after reporting NAV per share of $2.68 as of September 30, 2017; third consecutive quarter of NAV growth )
- ABY +6.7% (Algonquin to purchase 25% interest in Atlantica Yield from Abengoa at price of $24.25 per share, $2,430 million implied total equity value)
- HTGM +4.9% (enters into second statement of work with QIAGEN)
- RWLK +3.6% (announces that Germany's national social accident agrees to provide personal exoskeletons to qualifying beneficiaries)
- CGEN +3.4% (enters research collaboration with Mount Sinai on novel Myeloid Immuno-Oncology target)
Analyst comments:
- AMED +6.6% (upgraded to Buy from Neutral at Mizuho)
- HLS +3.7% (upgraded to Buy from Neutral at Mizuho)
- TRHC +2.1% (initiated with an Overweight at First Analysis Sec)
- TPR +1.4% (initiated with a Positive at Susquehanna)
- EQIX +1.1% (upgraded to Overweight from Neutral at JP Morgan)
- DPZ +1% (upgraded to Buy at Maxim Group)
- DVN +0.8% (upgraded to Overweight from Equal-Weight at Stephens)
